Photo: Collected-
Metropolis Desk-
On the occasion of Republic Day, Health Minister Mansukh Mandaviya introduced the first intranasal Covid 19 vaccination in the world, which was produced in India.
Bharat Biotech International Limited (BBIL) and Biotechnology Industry Research Assistance (BIRAC), a PSU within the Dept. of Biotechnology, worked together to develop the vaccine named iNCOVACC.
The vaccine was authorized by the Drugs Controller General of India (DCGI) for restricted emergency use as a booster dose in adults.
At the time, Mandaviya said that more than 65% of the vaccinations delivered worldwide come from India, a wonderful testimony to the cry for Atmanirbhar Bharat.
Jitendra Singh, the Union Minister of State (IC) for Science and Technology, Krishna Ella, the Co-Founder and Executive Chairman of Bharat Biotech, and other senior officials attended the event.
Because iNCOVACC does not require syringes, needles, alcohol wipes, bandages, or other injectable vaccine accessories, it is a more affordable alternative to injectable vaccinations in terms of procurement, distribution, storage, and disposal of biomedical waste.
It makes use of a vector-based platform that can quickly be upgraded with new versions, enabling large-scale production in a matter of months.
It is the ideal vaccine to combat future infectious diseases because of the quick response times and simple, inexpensive intranasal delivery.
